advanced search

RESPIRATORY

ADVANCED CAPSULE TECHNOLOGIES: DRY POWDER INHALERS TO TARGET DISEASE
EXPERT VIEW
Frédérique Bordes-Picard
ADVANCED CAPSULE TECHNOLOGIES: DRY POWDER INHALERS TO TARGET DISEASE
Frédérique Bordes-Picard  and Julien Lamps discuss the value of capsule-based dry powder inhalers in the modern respiratory market, the factors driving development in this area and considerations for matching a capsule to a device and formulation.
TFF AND UNION AGREE LICENSING PACT FOR TFF TECHNOLOGY WITH NICLOSAMIDE FOR THE TREATMENT OF COVID-19
TFF AND UNION AGREE LICENSING PACT FOR TFF TECHNOLOGY WITH NICLOSAMIDE FOR THE TREATMENT OF COVID-19
UNION therapeutics has acquired an option to a worldwide, exclusive licence to TFF Pharmaceuticals' Thin Film Freezing (TFF) technology, in combination with niclosamide, covering oral and inhalation formulations, potentially for covid-19, as well as other niclosamide-based therapies.
POLYMERIC EMI SHIELDING: PROVIDING A MORE SECURE FUTURE FOR PATIENTS
CONNECTIVITY
Marnik Vaes
POLYMERIC EMI SHIELDING: PROVIDING A MORE SECURE FUTURE FOR PATIENTS
Marnik Vaes, Leen-Pieter Deurloo and Martin Sas discuss the role of polymeric electromagnetic interference shielding in providing a more secure future for patients in a connected world.
INTERVIEW WITH SAI SHANKAR, ADAM SHAIN & MARCUS BATES
INTERVIEW
Sai Shankar
Aptar Pharma
INTERVIEW WITH SAI SHANKAR, ADAM SHAIN & MARCUS BATES
Sai Shankar, Adam Shain and Marcus Bates discuss the full potential of connectivity, coronavirus as a potential accelerator of adoption, and the place of connected drug delivery systems within Aptar Pharma’s broader offering to industry.
UNLOCKING INSIGHT FOR PATIENT SUPPORT PROGRAMMES
CONNECTIVITY
Neil Williams
Phillips Medisize
UNLOCKING INSIGHT FOR PATIENT SUPPORT PROGRAMMES
Neil Williams and Andrew Tubb discuss how insights delivered by a cloud-based connected health system help patient support programmes to monitor and improve medication adherence.
Adding value to Drug Delivery with Connectivity
VIDEO
Kevin Deane
Phillips Medisize
Adding value to Drug Delivery with Connectivity
In this video presentation, Kevin Deane looks at how connectivity applied in drug delivery technologies can provide better solutions for patients and for industry and add value for all stakeholders.
Chalmers University Pilot Project Developing Nasal spray to deliver vaccine against COVID-19
Chalmers University Pilot Project Developing Nasal spray to deliver vaccine against COVID-19
A unique concept for a nasal spray mRNA vaccine against covid-19 is being investigated in a new pilot project. The Swedish group is exploring design principles for nasal immunisation, developing a biomimetic​ nanoparticle provided with both immune enhancers and a targeting protein.
SENSOR ADVANCEMENTS IN DRUG DELIVERY IMPROVE COMPLIANCE
EXPERT VIEW
Salvatore Forte
SENSOR ADVANCEMENTS IN DRUG DELIVERY IMPROVE COMPLIANCE
Salvatore Forte discusses various advancements in sensors that are transforming drug delivery systems, making complex devices more automated, easier to use, and improving patient compliance as a result.
EU MDR DEADLINE DELAY: WHAT DOES IT MEAN FOR THE MEDICAL DEVICE INDUSTRY?
EXPERT VIEW
Beth Crandall
EU MDR DEADLINE DELAY: WHAT DOES IT MEAN FOR THE MEDICAL DEVICE INDUSTRY?
With the compliance deadline for the EU Medical Device Regulation recently delayed by a year due to the novel coronavirus pandemic, Beth Crandall looks at what it means for the medical device industry.
Senzer to Create Targeted Inhaled Antivirals for COVID-19
Senzer to Create Targeted Inhaled Antivirals for COVID-19
Senzer Pharmaceuticals has launched a Critical Care Division, which will utilise its expertise in respiratory pharmaceuticals to create targeted antiviral treatments for covid-19.
Telemedicine gains acceptance amid the Covid-19 pandemic
Joe Reynolds
Noble
Telemedicine gains acceptance amid the Covid-19 pandemic
Noble highlights how telemedicine is poised to become a mainstream alternative to the traditional in-person methods of care delivery, with the covid-19 pandemic easing barriers to acceptance and introducing patients to the safety and convenience of telehealth technology.
KEY NOSE CELLS IDENTIFIED AS LIKELY COVID-19 VIRUS ENTRY POINTS
KEY NOSE CELLS IDENTIFIED AS LIKELY COVID-19 VIRUS ENTRY POINTS
Researchers from the Human Cell Atlas Lung Biological Network, have identified two specific cell types in the nose as likely initial infection points for COVID-19 coronavirus, and cells in the eye and some other organs that also contain the viral-entry proteins. They also predict how a key entry protein is regulated with other immune system genes and reveals potential targets for the development of treatments to reduce transmission.
ANSYS simulations to help provide insights in fight against COVID-19
ANSYS, Inc
ANSYS simulations to help provide insights in fight against COVID-19
ANSYS, Inc, has posted sample clips of various simulations on its webpage, for others to use to gain insights in the fight against COVID-19. The simulations, which can be viewed here, offer various insights on aspects.
Pulmonary Delivery Could Make Niclosamide Effective Against COVID-19
Pulmonary Delivery Could Make Niclosamide Effective Against COVID-19
A novel inhaled formulation of the approved antihelminthic drug, niclosamide, is under development at the College of Pharmacy at The University of Texas at Austin for COVID-19. The compound was recently confirmed to exhibit antiviral efficacy in SARS-COV-2 infected cells and indeed was more potent compared with chloroquine, lopinavir and remdesivir, the group said. 
IS NOW THE TIME TO SHAKE UP THE pMDI ENVIRONMENT?
RESPIRATORY
Chris Baron
Aptar Pharma
IS NOW THE TIME TO SHAKE UP THE pMDI ENVIRONMENT?
Chris Baron explores how the use of propellants in pressurised metered dose inhalers has evolved – and how alternative propellants could be a catalyst for greater patient adherence.
NEW DRUG-NEBULISER COMBINATION PRODUCTS: CONSIDERATIONS BEYOND PERFORMANCE
RESPIRATORY
Dr Nicolas Schwenck
PARI
NEW DRUG-NEBULISER COMBINATION PRODUCTS: CONSIDERATIONS BEYOND PERFORMANCE
Nicolas Schwenck and Michael Hahn summarise the critical success factors for bringing a new vibrating membrane nebuliser for a drug-device combination product to the market. They highlight opportunities and pitfalls – starting from the evaluation phase, through the development phase and finally during commercialisation.
OPTIMISING NASAL DRUG PRODUCTS FOR SYSTEMIC DELIVERY
NASAL
David Ward
Intertek Pharmaceutical Services
OPTIMISING NASAL DRUG PRODUCTS FOR SYSTEMIC DELIVERY
David Ward discusses the benefits of systemic nasal delivery, describes a number of formulation strategies, and explains how to optimise absorption through properly informed formulation and device selection.
RETRONOSE: IMPROVING NASAL DELIVERY THROUGH A NEW AND IMPROVED DEVICE
NASAL
Dr Laurent Vecellio
Nemera
RETRONOSE: IMPROVING NASAL DELIVERY THROUGH A NEW AND IMPROVED DEVICE
Laurent Vecellio, Déborah Le Pennec, Guillaume Grevin and Alain Regard evaluate the performance of the RetroNose nasal drug delivery device.
OFF-THE-SHELF OR CUSTOM-MADE? CHOOSING A DRY POWDER INHALER
PULMONARY
Dr Philippe Rogueda
Merxin Ltd
OFF-THE-SHELF OR CUSTOM-MADE? CHOOSING A DRY POWDER INHALER
Philippe Rogueda discusses the manifold factors that need to be taken into account when choosing a dry powder inhaler – beyond just the target disease, formulation and patient population.
THE IMPORTANCE OF TRAINING AND ONBOARDING FOR INTRANASAL RESCUE THERAPIES
NASAL
Joe Masci
Noble
THE IMPORTANCE OF TRAINING AND ONBOARDING FOR INTRANASAL RESCUE THERAPIES
With a recent resurgence in nasal drug repurposing, Joe Masci looks at the importance of training and onboarding for intranasal rescue therapies.
RESPIRATORY DRUG DELIVERY: THEN, NOW AND SOON
EXPERT VIEW
Brennan Miles
RESPIRATORY DRUG DELIVERY: THEN, NOW AND SOON
Brennan Miles takes a look back at respiratory drug delivery over the last few decades to see what we can learn from the past – and looks ahead to what the future might look like, covering sustainability, device regulation, and formulation milestones.
PUBLIC INTEREST & INCENTIVES FOR INNOVATORS OF INHALED PRODUCTS
EXPERT VIEW
Dr Igor Gonda
PUBLIC INTEREST & INCENTIVES FOR INNOVATORS OF INHALED PRODUCTS
Igor Gonda, David Cipolla and Philippe Rogueda discuss the changes needed to increase the number of approved generic orally inhaled drug products (OIDPs) whilst providing additional incentives to innovators to meet the needs of the general public.
ADVANCING ASPRIHALE<sup>®</sup> TO PIVOTAL PK/PD STUDY
RESPIRATORY
Mark Stansfield
ADVANCING ASPRIHALE® TO PIVOTAL PK/PD STUDY
Mark Stansfield and Kambiz Yadidi discuss results of their pilot Phase I clinical study of dry-powder inhalation of aspirin.
HOSOKAWA EXTENDS BLENDER RANGE FOR DPI FORMULATIONS
RESPIRATORY
Bert Dekens
HOSOKAWA EXTENDS BLENDER RANGE FOR DPI FORMULATIONS
Bert Dekens announces the extension of the the company’s established Cyclomix modular blending technology range, to include small (R&D) scale, mid-range and large-scale systems.
Top